Go to content
UR Home

Case report: Predictability of clinical response and rejection risk after immune checkpoint inhibition in liver transplantation

URN to cite this document:
DOI to cite this document:
Yang Zhou, Jordi ; Eder, Dominik ; Weber, Florian ; Heumann, Philipp ; Kronenberg, Katharina ; Werner, Jens M. ; Geissler, Edward K. ; Schlitt, Hans J. ; Hutchinson, James A. ; Bitterer, Florian
[img]License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 25 Aug 2023 13:04


Background: The approval of Atezolizumab / Bevacizumab therapy (Atezo/Bev) in 2020 opened up a promising new treatment option for patients with end-stage hepatocellular carcinoma (HCC). However, liver transplant (LTx) patients with HCC are still denied this therapy owing to concerns about ICI-induced organ rejection and lack of regulatory approval. Methods: A prospective observational study at ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons